Preliminary program:
Printable edition (PDF)

Day 1 - Wednesday 18. May

Registration and welcome
07:00- Registration

08:30-08:45
Opening and welcome
Enrico Mihich,
Hans-Peter Huber,
Anne-Lise Børresen-Dale
08:45-09:30
Tannlege Olaf Aase og Fruens minneforelesning:
Opening keynote on P4 and cancer
Leroy Hood

Session I: Genetic Profiling of Patients, Prediction of Risk and therapy response
09:30-10:00
Gene network approaches to understanding polygenic risk
Bruce Ponder
Cancer Research Institute
Cambridge, UK
10:00-10:10
Discussion

10:10-10:40
Coffee break

10:40-11:10
Germline genetic variation and ovarian cancer risk: the clinical significance
Paul Pharoah
Strangeways Research Laboratory
Cambridge, UK
11:00-11:20
Discussion

11:20-11:35 Short poster presentation, selected from abstracts

Session II: Molecular Profiling of Tumors and Metastases
11:35-12:05
Genome-guided Precision Cancer Medicine
Elaine Mardis
The Genome Inst., Washington Univ
St. Louis, Missouri, USA
1205-12:15
Discussion

12:15-12:30
Short poster presentation, selected from abstracts

12:30-13:45
Lunch, poster viewing and exhibition
13:45-14:15
Genome scale molecular profiling provides a robust way to identify and qualify key biological processes driving cancer with the potential to personalize cancer treatment
Zoltan Szallasi
Technical University of Denmark
14:15-14:25
Discussion
14:25-14:55
Genomic-driver based stratification of breast cancer
Carlos Caldas
Cancer Research Institute
Cambridge UK
14:55-15:05
Discussion

15:05-15:20
Short poster presentation, selected from abstracts

15:20-15:40
Coffee break

15:40-16:10
Molecular Archaeology of Cancer
Peter van Loo
Crick Center
London, UK
16:10-16:20
Discussion

16:20-16:50
Genomic Analysis of Breast Tumors and Biomarkers of Therapeutic Responsiveness
Charles M. Perou
UNC - Chapel Hill
North Carolina, USA
16:50-17:00
Discussion

17:30  The bus for the social event at the City Hall leaves.
The event there starts at 19:00.



Day 2 - Thursday 19. May
Session III: Tumor-host Microenvironment Interaction and Metabolism
07:30-08:30
Satellite meeting hosted by Illumina. Light breakfast served.

08:30-09:00
Li-Fraumeini Syndrome: The role of inherited p53 mutations in human tumor developent
Arnold Levine
Institute for Advanced Study
Princeton, USA
09:00-09:10
Discussion

09:10-09:25
Short poster presentation, selected from abstracts
09:25-09:55
Deconvolution of the triple-negative breast cancer microenvironment
Morag Park
McGill University
Montreal, Canada
09:55-10:05
Discussion

10:05-10:35
Coffee break

10:35-11:05
New insights into the role of microenvironment in breast morphogenesis and breast cancer: The last 10 years
Mina Bissell
Lawrence Berkeley National Laboratory
California, USA
11:05 -11:15
Discussion

11:15-11:30
Short poster presentation, selected from abstracts


Session IV: Targeted Therapy
11:30-12:00
Overcoming challenges to the delivery of personalized medicine
Gordon Mills
MD Anderson Cancer Center
Houston, Texas, USA
12:00-12:10
Discussion

12:10-13:35
Lunch, poster viewing and exhibition

13:35 - 14:05
EACR Lecture: Synthetic lethal drug combinations for the treatment of cancer
Rene Bernards
The Netherlands Cancer Institute
Netherlands
14:05-14:15
Discussion

14:15-14:45
Understanding and managing breast cancer as a complex adaptive system
Joe Gray
Knight Cancer Inst, Oregon Health & Sci Univ
Oregon, USA
14:45-14:55
Discussion

14:55-15:25
Heterogeneity, drug resistance and clonal evolution in colorectal cancer
Alberto Bardelli
University of Torino
Italy
15:25-15:35
Discussion

15:35-16:05
Coffee break

16:05-16:35
Intracellular antigens as a source of targets of antibody-based immunotherapy for the treatment of
Soldano Ferrone
Massachusetts General Hospital, Harvard
Boston, USA
16:35-16:45
Discussion

16:45-18:30
Satellite meeting with panel discussion hosted by Roche; snacks and wine served

19:00- Social event at Holmenkollen Ski Arena



Day 3 - Friday 20. May
Session V: Translation
07:30-08:00 Satellite meeting hosted by AstraZeneca; light breakfast served

08:30-09:00
Applying molecular profiling in cancer
Christof von Kalle
German Cancer Research Center (DKFZ)
Germany
09:00-09:10
Discussion

09:10-09:40
Biomarker indication for increased likelihood of therapeutic response
Laura van't Veer
University of California
San Francisco, USA
09:40-09:50
Discussion

09:50-10:20
Coffee break

10:20-10:50
Translation biology into therapeutics; clinical beacons mapping the terrain
Per Eystein Lønning
University of Bergen
Norway
10:50-11:00
Discussion

11:00-11:30
Breast tumor heterogeneity: A challenge for translation
Anne-Lise Børresen-Dale
Oslo University Hospital
Norway
11:30-11:40
Discussion


Session VI: The impact of social and ethical issues on personalized medicine
11:40-12:10
Social and ethical perspectives
Eva Winkler
NCT
Germany
12:10-12:20
Discussion


Summary and highlights:
_
12:20-12:30
Poster prize sponsored by EACR
12:30-12:50
Summary and highlights, concluding remarks
Kurt Zänker
Institute for Immunology, Univ. Witten and
The Fritz Bender Foundation, Germany
12:50-13:00
Closing
Anne-Lise Børresen-Dale
Oslo University Hospital
Norway
13:00- Lunch, exhibition